13 Results

People

  1. Schoder
    Schoder
  2. Younes
    Younes
  3. Zelenetz
    Zelenetz
  4. Kumar
    Kumar
  5. Matasar
    Matasar
  6. Gerecitano
    Gerecitano
  7. Hamlin
    Hamlin
  8. Moskowitz
    Moskowitz
  9. Moskowitz
    Moskowitz
  10. Straus
    Straus

Groups

  1. Center for Hematologic Malignancies (13)
  2. Department of Medicine (13)
  3. Hematologic Malignancies, Division of (13)
  4. Lymphoma (13)
  5. Molecular Imaging and Therapy Service (13)
  6. Radiology, Department of (13)
  7. Executive Committee, Center for Hematologic Malignancies (9)
  8. Survivorship Research (8)
  9. Biostatistics Service (7)
  10. Epidemiology and Biostatistics (7)
  1. "Center for Hematologic Malignancies"
  2. "Lymphoma"
  3. "Molecular Imaging and Therapy Service"
  4. "2017"
Formats
  1. Meeting Abstract (9)
  2. Journal Article (4)
Groups
  1. Center for Hematologic Malignancies (13)
  2. Department of Medicine (13)
  3. Hematologic Malignancies, Division of (13)
  4. Lymphoma (13)
  5. Molecular Imaging and Therapy Service (13)
  6. Radiology, Department of (13)

More Groups

People
  1. Heiko Schoder (12)
  2. Anas Younes (9)
  3. Andrew Zelenetz (9)
  4. David Straus (9)
  5. Anita Kumar (8)
  6. Matthew Matasar (8)

More People

Years
  1. 2017 (13)
Publications
  1. Hematological Oncology (5)
  2. Blood (4)
  3. American Journal of Roentgenology (1)
  4. Annals of Oncology (1)
  5. Journal of Clinical Oncology (1)
  6. Medicine (1)
Publishers
  1. Wiley Blackwell (5)
  2. American Society of Hematology (4)
  3. American Roentgen Ray Society (1)
  4. American Society of Clinical Oncology (1)
  5. Oxford University Press (1)
  6. Wolters Kluwer Health, Inc (1)

Results (13)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase I dose escalation of ibrutinib and buparlisib in relapsed/refractory diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and follicular lymphoma (FL)
    Meeting Abstract

    Batlevi, C. L.; Hamlin, P. A.; Matasar, M. J.; Horwitz, S. M.; Gerecitano, J. F.; Moskowitz, C. H.; Straus, D. J.; Zelenetz, A. D.; Drullinsky, P.; Copeland, A.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • A phase Ib/IIa trial of the combination of romidepsin, lenalidomide and carfilzomib in patients with relapsed/refractory lymphoma shows complete responses in relapsed and refractory B-and T-cell lymphomas
    Meeting Abstract

    Mehta-Shah, N.; Moskowitz, A. J.; Lunning, M. A.; Lynch, P.; Scheuerman, M.; Minnal, V.; Galasso, N.; Kumar, A.; Gerecitano, J.; Zelenetz, A. D.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • A pilot study of brentuximab vedotin and AVD chemotherapy followed by 20 Gy involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma
    Meeting Abstract

    Kumar, A.; Casulo, C.; Advani, R. H.; Budde, L.; Barr, P. M.; Batlevi, C. L.; Caron, P.; Chen, R. W.; Constine, L. S.; Courtien, A.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Prognostic utility of serum TARC, MDC, IL10, and soluble CD163 levels with positron emission tomography (PET) response-adapted therapy for advanced-stage Hodgkin lymphoma (HL): A SWOG S0816 US Intergroup correlative study
    Meeting Abstract

    Hsi, E. D.; Li, H.; Nixon, A. B.; Evens, A. M.; Schoder, H.; Straus, D. J.; Bartlett, N. L.; Sweetenham, J. W.; Barr, P. M.; Fanale, M. A.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Specialized second-opinion radiology review of PET/CT examinations for patients with diffuse large B-cell lymphoma impacts patient care and management
    Journal Article

    Sawan, P.; Rebeiz, K.; Schoder, H.; Batlevi, C.; Moskowitz, A.; Ulaner, G. A.; Dunphy, M.; Mannelli, L.
    Medicine (2017)

    Fulltext@MSK | Save
  • Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma
    Journal Article

    Moskowitz, A. J.; Schòˆder, H.; Gavane, S.; Thoren, K. L.; Fleisher, M.; Yahalom, J.; McCall, S. J.; Cadzin, B. R.; Fox, S. Y.; Gerecitano, J.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)
    Journal Article

    Younes, A.; Hilden, P.; Coiffier, B.; Hagenbeek, A.; Salles, G.; Wilson, W.; Seymour, J. F.; Kelly, K.; Gribben, J.; Pfreunschuh, M.; more...
    Annals of Oncology (2017)

    Fulltext@MSK | Save
  • A Phase I study of ibrutinib combined with rituximab, ifosfamide, carboplatin, and etoposide in patients with relapsed or primary diffuse large B-cell lymphoma
    Meeting Abstract

    Sauter, C. S.; Matasar, M. J.; Schoder, H.; Drullinsky, P.; Gerecitano, J.; Kumar, A.; Noy, A.; Palomba, M. L.; Portlock, C. S.; Straus, D. J.; more...
    Hematological Oncology (2017)

    Fulltext@MSK | Save
  • A pilot study of brentuximab vedotin and AVD chemotherapy followed by 20 Gy involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma
    Meeting Abstract

    Kumar, A.; Casulo, C.; Advani, R.; Budde, E.; Barr, P. M.; Batlevi, C. L.; Chen, R.; Constine, L. S.; Courtien, A. I.; Dandapani, S. V.; more...
    Hematological Oncology (2017)

    Fulltext@MSK | Save
  • The 23-gene gene expression-based assay does not predict interim PET scan results after ABVD in advanced stage classical Hodgkin lymphoma in the US Intergroup S0816 trial
    Meeting Abstract

    Scott, D. W.; Li, H.; Harvey, Y.; Chan, F.; Mottok, A.; Boyle, M.; Evens, A. M.; Schoder, H.; Straus, D. J.; Bartlett, N. L.; more...
    Hematological Oncology (2017)

    Fulltext@MSK | Save